[Update in multiple myeloma: international criteria for treatment response and renal complications].
Decaux
O
O
Service de médecine interne, hôpital Sud, 16, boulevard de Bulgarie, 35203 Rennes cedex, France. olivier.decaux@chu-rennes.fr
Karras
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005602:France / Q000453:epidemiology; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D007145:Immunoglobulin kappa-Chains / Q000097:blood; D007146:Immunoglobulin lambda-Chains / Q000097:blood; D007155:Immunologic Factors / Q000097:blood*; D007391:International Cooperation; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications* / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011719:Pyrazines / Q000627:therapeutic use; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000175:diagnosis / Q000209:etiology; D012680:Sensitivity and Specificity; D012955:Societies, Medical
D000970:Antineoplastic Agents; D015415:Biomarkers; D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D007155:Immunologic Factors; D011719:Pyrazines; D000069286:Bortezomib